Latest news

Thumbnail image for NICE publishes final draft guidelines backing GSK’s Strimvelis

NICE publishes final draft guidelines backing GSK’s Strimvelis

Cost regulators for NHS funded therapies in England and Wales have now published final draft guidance approving GlaxoSmithKline’s gene therapy Strimvelis for an ultra-rare immune deficiency condition commonly referred to as bubble baby syndrome.

3rd January 2018

Thumbnail image for GW’s cannabinoid Epidiolex under EU, US review

GW’s cannabinoid Epidiolex under EU, US review

Regulators on both sides of the Atlantic are now reviewing GW Pharmaceuticals’ cannabinoid Epidiolex as a potential treatment for seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome.

2nd January 2018

Thumbnail image for Roche to buy Ignyta for $1.7 billion

Roche to buy Ignyta for $1.7 billion

Roche has announced plans to buy US group Ignyta for $27 a share in an all-cash deal totaling around $1.7 billion, securing itself access to the latter’s experimental cancer medicines.

2nd January 2018

Thumbnail image for Breakthrough status for Pfizer/Merck’s avelumab combo

Breakthrough status for Pfizer/Merck’s avelumab combo

Merck and Pfizer’s avelumab has picked up its second breakthrough therapy status in the US, this time for use in combination with Inlyta for treatment-naïve patients with advanced renal cell carcinoma (RCC).

22nd December 2017

Thumbnail image for AZ and ICL link to research respiratory diseases

AZ and ICL link to research respiratory diseases

AstraZeneca and Imperial College London have announced plans to work together on investigating the scientific mechanisms and underlying drivers of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).

22nd December 2017

Thumbnail image for Janssen buys into Legend’s CART therapy

Janssen buys into Legend’s CART therapy

Janssen has entered into a global collaboration and license agreement with Legend Biotech USA and Legend Biotech Ireland to develop, manufacture and commercialise experimental CART-cell therapy LCAR-B38M.

22nd December 2017

Thumbnail image for NHS England consults on curbing OTC prescriptions

NHS England consults on curbing OTC prescriptions

NHS England has launched a consultation on proposals to cut back on prescriptions for some over the counter products such as dandruff shampoo and drops for tired eyes, in order to garner savings of £136 million.

21st December 2017

Thumbnail image for Green light for Perjeta/Herceptin combo

Green light for Perjeta/Herceptin combo

Roche group Genentech has secured approval of Perjeta in combination with Herceptin (trastuzumab) and chemotherapy for adjuvant treatment of a specific type of early breast cancer in the US.

21st December 2017

Thumbnail image for NICE proposes restricting MS therapies

NICE proposes restricting MS therapies

Novartis’ Extavia is the only beta interferon being endorsed by the National Institute for Health and Care Excellence as a cost-effective treatment option for multiple sclerosis.

21st December 2017

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download